Endonovo Therapeutics (OTCQB: ENDV) today announced its collaboration with a Stanford University sponsored Orthopedic Shoulder and Knee Study to determine benefits of Endonovo’s tPEMF SofPulse(R) on pain, medication levels and physical function post-operatively. According to the update, the study will evaluate 76 patients with Active and Sham Comparator groups, measured by visual analog scale (“VAS”), … Continue reading “NetworkNewsBreaks – Endonovo Therapeutics, Inc. (ENDV) Collaborates with a Stanford University Sponsored Orthopedic Shoulder and Knee Study”
Endonovo Therapeutics (OTCQB: ENDV) today announced the evaluation of its SofPulse(R) device at major universities for orthopedic surgeries. Endonovo’s FDA-Cleared SofPulse(R) is a non-invasive device utilized for the reduction of postoperative pain and edema and represents a low-cost drug-free solution for reducing opioid usage, accelerating patient recovery and preventing opioid addiction following surgical procedures. “We … Continue reading “NetworkNewsBreaks – Endonovo Therapeutics, Inc. (ENDV) Collaborates with Major Universities for the Evaluation of SofPulse(R) for Orthopedic Surgeries”
Endonovo Therapeutics (OTCQB: ENDV) today announced the reduction of current liabilities and restructuring of the balance sheet through the approved modification of the terms of the Preferred C shares. “Strengthening our balance sheet is a priority we feel is instrumental in our continued and long-term success. This reduction of debt provides us the flexibility to … Continue reading “NetworkNewsBreaks – Endonovo Therapeutics, Inc. (ENDV) Reduces Debt, Restructures Balance Sheet”
Endonovo Therapeutics (OTCQB: ENDV) today announced that it has secured sales of SofPulse(R), the company’s FDA-Cleared, non-invasive device utilized for the reduction of postoperative pain and edema, to multiple plastic surgery centers. “SofPulse(R) main distribution model is marketing to major hospitals throughout the US and is beginning to be viewed as the standard of care … Continue reading “NetworkNewsBreaks – Endonovo Therapeutics, Inc. (ENDV) Receives SofPulse(R) Orders From Multiple Plastic Surgery Centers”
Endonovo Therapeutics (OTCQB: ENDV) today announced initial sales of SofPulse(R) units into a VA hospital in Texas. Endonovo’s FDA-Cleared non-invasive device for reduction of postoperative pain and edema, SofPulse(R) represents a low-cost, drug-free solution to reduce use of opioids following surgical procedures and help prevent addiction. “I am extremely proud of our team and the … Continue reading “NetworkNewsBreaks – Endonovo Therapeutics, Inc. (ENDV) Announces Initial Sales of SofPulse(R) Units to a Texas-Based VA Hospital”
Endonovo Therapeutics (OTCQB: ENDVD) today announced that the United States Patent and Trademark Office (“USPTO”) has issued a U.S. Patent for Application No. 15/549,748 covering method and apparatus for electromagnetic treatment of multiple sclerosis (“MS”). “This issuance follows our prior patents related to the methods of treating post-operative pain and edema,” Endonovo’s Chief Medical Officer … Continue reading “NetworkNewsBreaks – Endonovo Therapeutics, Inc. (ENDVD) Secures Broad Patent Covering Electromagnetic Treatment of MS”
Endonovo Therapeutics (OTCQB: ENDVD) today announced that the United States Patent and Trademark Office (“USPTO”) has issued U.S. Patent No. 15217855, which is directed to the usage of an Apparatus and Method for Electromagnetic Treatment of Neurological Injury or Condition Caused by a Stroke. “We are extremely pleased with the continued development and expansion of … Continue reading “NetworkNewsBreaks – Endonovo Therapeutics, Inc. (ENDVD) Announces Issuance of U.S. Patent, Expansion of its SofPulse(R) Intellectual Property Portfolio”
Endonovo Therapeutics (OTCQB: ENDVD), a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, today announced the delivery of SofPulse(R) evaluation units to all thirty-two National Football League (“NFL”) teams. “With injuries affecting the NFL more than any other professional sports league, we are pleased to support the health of NFL players by providing SofPulse(R) evaluation units … Continue reading “NetworkNewsBreaks – Endonovo Therapeutics Inc. (ENDVD) Provides SofPulse(R) Evaluation Units to All NFL Teams”
Endonovo Therapeutics (OTCQB: ENDVD), a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, recently announced that its previously announced 1-for-1,000 reverse split of its common stock became effective as of December 19, 2019. Starting today, December 20, 2019, Endonovo’s common stock will trade on the OTC market under the trading symbol ‘ENDVD’ on a split-adjusted basis … Continue reading “NetworkNewsBreaks – Endonovo Therapeutics Inc. (ENDVD) Reverse Split of Common Stock Becomes Effective”
Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, today announced that the company has determined to effect a 1-for-1,000 reverse stock split of its issued common shares. According to the update, the reverse stock split will take effect, and the company’s common stock will begin trading on a split-adjusted basis on … Continue reading “NetworkNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Announces Plans to Effect Reverse Stock Split”
